Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + docetaxel + cisplatin
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Camrelizumab + docetaxel + cisplatin is a combination regimen used primarily in oncology clinical trials, especially for the treatment of advanced or metastatic solid tumors such as esophageal squamous cell carcinoma (ESCC) and other cancers. Camrelizumab is a humanized monoclonal antibody targeting programmed death-1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Docetaxel and cisplatin are cytotoxic chemotherapeutic agents; docetaxel is a taxane that inhibits microtubule depolymerization, while cisplatin forms DNA crosslinks leading to apoptosis. The combination aims to leverage both immunotherapy and chemotherapy mechanisms for synergistic anti-cancer effects[1][3][4][8].
- Brand names
- AiRuiKa
- Other names
- camrelizumab plus TPcamrelizumab plus TP chemotherapyTP-Hospital of Stomatology, Wuhan University-oral squamous cell carcinoma
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on camrelizumab + docetaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + docetaxel + cisplatin.